Skip to content

Pfizer inks deal with Vivet Therapeutics in liver disorder

September 23, 2020

Pfizer (NYSE:PFE) and Vivet Therapeutics, a privately held gene therapy biotech company have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and life-threatening liver disorder.

Terms of the agreement were not disclosed. The trial is expected to commence in early 2021.

The Phase 1/2 clinical supply for VTX-801 will be manufactured in Pfizer’s facility in Chapel Hill, North Carolina.

In March 2019, Pfizer acquired 15% ownership stake in Vivet and collaborated for the development of VTX-801.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: